- Medexus (MDP) has secured Canadian rights to commercialize terbinafine hydrochloride nail lacquer, which is supplied by Polichem, an Almirall group company focused on medical dermatological treatments for skin health
- The product, which is used to treat fungal nail infections, will be submitted for Health Canada approval later this year
- The company expects the product to grow its Canadian revenues
- Medexus is a pharmaceutical company with a growing portfolio of innovative and rare disease treatment solutions
- Medexus Pharmaceuticals (MDP) opened today at $1.4 per share
Medexus (MDP) has acquired Canadian rights to commercialize terbinafine hydrochloride nail lacquer.
The product is designed to treat fungal nail infections and is supplied by Polichem, an Almirall group company that focuses on medical dermatological treatments for skin health.
Terbinafine hydrochloride is a strategic fit with Medexus’s market-leading product, Rupall, according to Richard Labelle, Medexus’s General Manager, Canadian Operations.
Ken d’Entremont, CEO of Medexus, believes that the product will grow Canadian revenues and engage the commercial infrastructure that the company has put in place to support Rupall.
The product will be submitted for Health Canada approval later this year.
Medexus’s sales force is already experienced in the dermatology field, and the product is seen as an important potential addition to the Canadian market.
Medexus estimates that the Canadian fungicides market is worth C$88 million annually.
Medexus will pay Polichem a low double-digit percentage royalty on net sales of the product, inclusive of supply price. The long-term license agreement also provides for a low upfront payment and four sales-based milestone payments.
Medexus is a pharmaceutical company with a growing portfolio of innovative and rare disease treatment solutions.
Medexus Pharmaceuticals (MDP) opened today at $1.4 per share.
